Movalis (meloxicam) ampoules 15 mg/1.5 ml. №5

Description

Movalis composition
active substance: 1.5 ml of the drug contains 15 mg of meloxicam;
Excipients: meglumine, glycofurol, poloxamer 188, sodium chloride, glycine, sodium hydroxide, water for injections.

Dosage form
Solution for injection.

Indications
Movalis is prescribed if the patient suffers from rheumatoid arthritis, arthrosis, osteoarthritis, ankylosing spondylitis, osteoarthritis and degenerative joint lesions.

Contraindications

• exacerbation of peptic ulcers of the stomach or duodenum;
• severe form of renal or hepatic failure;
• there is a pronounced “aspirin” triad, which includes aspirin intolerance, nasal sinus polyps and bronchial asthma.

The injectable form of Movalis is not prescribed to persons receiving anticoagulant treatment: this can cause intramuscular hematomas.

Children
Movalis , 15 mg / 1.5 ml solution for injection, is contraindicated in children

Application during pregnancy and lactation
Not assigned.

Method of administration and dosage

• With osteoarthritis, the daily rate of Movalis should not be more than 7.5 mg. In severe cases, it is possible to increase the dosage to 15 mg.
• With symptoms of rheumatoid arthritis, the daily dose of Movalis is 15 mg. If there is a positive trend in the treatment, then the dose can be halved, to 7.5 mg.
• With ankylosing spondylitis, the patient should receive 15 mg per day. The dose may be reduced to 7.5 mg.

In patients with a high likelihood of developing adverse reactions or renal insufficiency, the daily amount of the drug should not exceed 7.5 mg.

Overdose
In case of an overdose, there is an increase or the occurrence of adverse reactions from the administration of the drug.

Side effects
The drug is capable of negatively affecting various systems of the human body.

• In case of disruption of the digestive tract, it is possible to develop nausea, vomiting, pain in the abdomen, flatulence, increased or decreased stool. Also, with oral administration of the drug, belching, esophagitis, ulcerative lesions of the gastrointestinal tract, micro and macro gastrointestinal bleeding, gastritis and colitis may occur.
• On the part of the hematopoietic organs, when using the drug, the development of anemia, leukopenia and thrombocytopenia is sometimes observed.
• Taking the drug may be accompanied by the appearance of itchy skin, rashes, urticaria and photosensitivity.
• Sometimes taking Movalis can be accompanied by the development of acute attacks of suffocation or bronchial asthma.
• From the side of the nervous system, dizziness, increased drowsiness or nervous excitability, tinnitus, emotional lability may occur.
• On the part of the cardiovascular system, changes in blood pressure, heart palpitations and edema sometimes develop.
• From the side of the visual system, it is possible to impair the clarity of vision or the development of conjunctivitis.

Expiration date
3 years.

Storage conditions
Store in a place protected from sunlight, out of reach of children at a temperature not exceeding 25 ºC.